The DOI matches its Crossref record; 273 of the 279 references it cites were found in a registry or an index.
Delivering affordable cancer care in high-income countries
Abstract
The burden of cancer is growing, and the disease is becoming a major economic expenditure for all developed countries. In 2008, the worldwide cost of cancer due to premature death and disability (not including direct medical costs) was estimated to be US$895 billion. This is not simply due to an increase in absolute numbers, but also the rate of increase of expenditure on cancer. What are the drivers and solutions to the so-called cancer-cost curve in developed countries? How are we going to afford to deliver high quality and equitable care? Here, expert opinion from health-care professionals, policy makers, and cancer survivors has been gathered to address the barriers and solutions to delivering affordable cancer care. Although many of the drivers and themes are specific to a particular field-eg, the huge development costs for cancer medicines-there is strong concordance running through each contribution. Several drivers of cost, such as over-use, rapid expansion, and shortening life cycles of cancer technologies (such as medicines and imaging modalities), and the lack of suitable clinical research and integrated health economic studies, have converged with more defensive medical practice, a less informed regulatory system, a lack of evidence-based sociopolitical debate, and a declining degree of fairness for all patients with cancer. Urgent solutions range from re-engineering of the macroeconomic basis of cancer costs (eg, value-based approaches to bend the cost curve and allow cost-saving technologies), greater education of policy makers, and an informed and transparent regulatory system. A radical shift in cancer policy is also required. Political toleration of unfairness in access to affordable cancer treatment is unacceptable. The cancer profession and industry should take responsibility and not accept a substandard evidence base and an ethos of very small benefit at whatever cost; rather, we need delivery of fair prices and real value from new technologies.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The indirect economic costs associated with premature death and lost productivity from the growing cancer burden have been estimated at US$1.16 trillion a year,3 or approaching 2% of global GDP.103”
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Initial sequencing and analysis of the human genome
International Human Genome Sequencing Consortium, Whitehead Institute for Biomedical Research, C. F. G. R., Lander, E. S., Linton, L. M., Birren, B., Nusbaum, C., Zody, M. C., Baldwin, J., Devon, K., Dewar, K., et al. (2001) · Nature · doi:10.1038/35057062 · Cited by 24,216
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
Ferlay, J., Shin, H., Bray, F., Forman, D., Mathers, C. D., & Parkin, D. M. (2010) · International Journal of Cancer · doi:10.1002/ijc.25516 · Cited by 21,468
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Jemal, A., Siegel, R., Xu, J., & Ward, E. (2010) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20073 · Cited by 12,596
(1968) · American Association of Industrial Nurses Journal · doi:10.1177/216507996801601208 · Cited by 8,811
Early Palliative Care for Patients with Metastatic Non–Small-Cell Lung Cancer
Temel, J. S., Greer, J. A., Muzikansky, A., Gallagher, E. R., Admane, S., Jackson, V. A., Dahlin, C. M., Blinderman, C. D., Jacobsen, J., Pirl, W. F., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1000678 · Cited by 7,482
Cost-Effectiveness in Health and Medicine
(1996) · doi:10.1093/oso/9780195108248.001.0001 · Cited by 7,193
A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer
Paik, S., Shak, S., Tang, G., Kim, C., Baker, J. B., Cronin, M. T., Baehner, F. L., Walker, M. G., Watson, D., Park, T., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041588 · Cited by 6,321
Fisher, B., Anderson, S., Bryant, J., Margolese, R. G., Deutsch, M., Fisher, E. R., Jeong, J.-H., & Wolmark, N. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa022152 · Cited by 6,249
Research works printed but not linked: 2
- Jönsson, 2007, The burden and cost of cancer, Ann Oncol, 18, 8
- Stark, 2009, The burden of cancer in Europe and the availability of cancer drugs, EJHP Practice, 15, 20
Cited by
Sorted by citations
Items 501–600 of 719
Deficiencies of methods applied in cost effectiveness analysis of hematological malignancies
Batty, N., Shatzel, J. J., Wiles, S. P., Kabalan, M., Sharma, R. S., Pang, J., Yi, D. K., Alatovic, I., Saif, S., Narasimha, D., et al. (2014) · Journal of Cancer Policy · doi:10.1016/j.jcpo.2014.01.002 · Cited by 3
Health Economic Aspects of Breast Cancer Treatment: The Compulsory Health Insurances' View
Zimmer, B., & Heyll, A. (2013) · Breast Care · doi:10.1159/000346985 · Cited by 3
Clinical trials in drug development
Verweij, J. (2012) · Current Opinion in Oncology · doi:10.1097/cco.0b013e328351fb43 · Cited by 3
Daveson, B. A., Smith, M., Yi, D., McCrone, P., Grande, G., Todd, C. J., Gysels, M., Costantini, M., Murtagh, F. E., Higginson, I. J., et al. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011619.pub2 · Cited by 3
Evolving strategies for the management of multiple myeloma: a managed care perspective.
Im, K., Boccia, R. V., Cannon, E., Cardarelli, W. J., Gamble, B., House, L. S., Dh, H., Malloy, M., Rd, M., Milota, B., et al. (2014) · PubMed · Cited by 3
Rituximab biosimilar evaluated by network meta-analysis
Chiumente, M., Mengato, D., & Messori, A. (2017) · Haematologica · doi:10.3324/haematol.2017.175042 · Cited by 3
“2 The growing health-care needs and the increase of new and expensive healthcare technologies are a challenge for the sustainability of health systems worldwide.(1) Globally, national health systems are currently spending around US$ 100 billion per year only for anticancer drugs.”
360 Health Analysis (H360) – A Proposal for an Integrated Vision of Breast Cancer in Portugal
Instituto Português de Oncologia do Porto Francisco Gentil EPE, P., Coelho, S., Rego, I. B., Instituto Português de Oncologia de Coimbra Francisco Gentil EPE, C., Dionísio, M. R., Cavaco‐Silva, J., ScienceCircle − Scientific and Biomedical Consulting, L., Semedo, P. M., Pavão, F., Baptista‐Leite, R., et al. (2020) · European Journal of Breast Health · doi:10.5152/ejbh.2020.5144 · Cited by 3
“Factors that have been identified as potentially negatively impacting cancer outcomes include the centralization of services, patient lists per general practitioner, patients having unrestrained access to different primary care physicians, and access time to secondary care (9, 11).”
BackgroundInterrogating the Cancer Genome to Deliver More Precise Cancer Care
Mateo, J., & Bono, J. S. D. (2016) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_156908 · Cited by 3
Promises and pitfalls of new technology in radiotherapy
Guedea, F. (2012) · Clinical & Translational Oncology · doi:10.1007/s12094-012-0905-0 · Cited by 3
“As Sullivan [15] so accurately pointed out ‘‘the cancer profession and industry should take responsibility and not accept a substandard evidence base and an ethos of very small benefit at whatever cost’’.”
BackgroundThe Possible use of Inorganic Phosphate in Osteosarcoma Therapy
Naviglio, S. (2013) · Future Oncology · doi:10.2217/fon.13.95 · Cited by 3
Distributed learning and prediction modelling in radiation oncology
Deist (2019) · doi:10.26481/dis.20190405td · Cited by 3
Johnson, S., Tasker, R., Mired, D., Dcruz, A. K., & Adams, C. (2020) · JCO Global Oncology · doi:10.1200/go.20.00020 · Cited by 3
“Although we lack reliable estimates on global public health spending on cancer, we know that the costs of improperly or inadequately treated cancer exceed US$895 billion, clearly demonstrating the opportunity we have to make timely and effective investments in cancer care that can curb the burden of cancer and help al…”
BackgroundConfronting the problems we had hoped to avoid
Kunitoh, H., & Kakizoe, T. (2024) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyae131 · Cited by 3
Wang, S., Li, M., Cai, S., & Zhang, W. (2023) · World Journal of Surgical Oncology · doi:10.1186/s12957-023-02891-4 · Cited by 2
“Nearly 80% of 15 million cancer patients will undergo surgery and require anesthesia [2].”
BackgroundHigashi, R. T., Lee, J., Hernandez, Y., Ponton, M., Liao, J. M., Cross, K. C., & Billig, J. I. (2026) · Clinical Orthopaedics and Related Research · doi:10.1097/corr.0000000000003826 · Cited by 2
Kawczak, P., & Bączek, T. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15083024 · Cited by 2
Latif, M. A. M., Mazhar, S., Tasleem, M., Alqurashi, A. A., Arfan, M., , Z. A., & Zafar, M. B. (2026) · Drug Design Development and Therapy · doi:10.2147/dddt.s575152 · Cited by 2
“91”
Guidelines: Usefulness and Limitations
Gnant, M. (2013) · Breast Care · doi:10.1159/000353791 · Cited by 2
CANCER MORTALITY AND INCIDENCE IN SLOVAKIA AND THEIR SPATIAL SPECIFICS
Vilinová, K., Repaská, G., Dubcová, A., & Némethová, J. (2015) · International Scientific Conference Geobalcanica. Proceedings · doi:10.18509/gbp.2015.64 · Cited by 2
“Due to the population aging, most of developed countries face health and clinical problem [11].”
BackgroundGarcía‐Albéniz, X., Logan, R. W., Schrag, D., & Hernán, M. Á. (2014) · Medical Care · doi:10.1097/mlr.0000000000000231 · Cited by 2
van Harten, W., & Retèl, V. P. (2016) · ecancermedicalscience · doi:10.3332/ecancer.2016.686 · Cited by 2
Navigating Ethical Practices in the Era of High Cost Hematology
Ertz-Archambault, N. M., & Khera, N. (2020) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-020-00599-w · Cited by 2
Volatile and Intravenous Anesthetics and Cancer
Dubowitz, J. A., Rampes, S., Enlund, M., & Ma, D. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-69584-8.00011-6 · Cited by 2
Xu, W.-F., Yang, P., Wei, Z., Liu, J., Yan, R.-L., Chen, Q., Tong, R.-X., Xu, S.-Y., Gao, W.-Q., Zhang, W., et al. (2023) · Current Medical Science · doi:10.1007/s11596-022-2682-5 · Cited by 2
Rojas-Díaz, D., Puerta-Yepes, M. E., Medina, D., Botero, J. A., Rodríguez, A., & Rojas, N. (2023) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph20186740 · Cited by 2
“The Lancet Oncology Commission [59] has compiled evidence and outlined key measures in this regard, including the promotion of low-cost innovations, the increased use of off-patent products, more research on comorbidities, and reducing the number of technologies that only provide marginal benefits.”
BackgroundRostoft, S., Thomas, M. J., Slaaen, M., Møller, B., Nesbakken, A., & Syse, A. (2023) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2023.101683 · Cited by 2
Invisible cancers: Seeing, knowing, enacting and proving cancers in Haiti
Henderson, R. R. (2024) · Social Science & Medicine · doi:10.1016/j.socscimed.2024.116733 · Cited by 2
Liang, X., Meng, M., Qin, S., Chen, X., & Li, Y. (2024) · Scientific Reports · doi:10.1038/s41598-024-65474-7 · Cited by 2
“It is often less cost-effective to combine innovative drugs with existing treatment schemes due to the drastic increase in costs and the uncertainty of survival benefits 32 .”
General practice utilisation by Australian cancer patients in the last year of life
Grant, M. P., McCarthy, D., Kearney, C., Collins, A., Sundararajan, V., Rhee, J., Philip, J. A. M., & Emery, J. D. (2024) · Family Practice · doi:10.1093/fampra/cmae062 · Cited by 2
“International studies have demonstrated that the involvement of general practitioners (GPs) during this period increases the probability of dying at home, decreases hospitalisations and health care expenditure, and reduces aggressive interventions at the end of life [4–7].”
A Review on Pharmacogenomics of Anticancer Drugs in Targeted Therapy
Chiranth, C. R., Kumkum, S., Yellapur, S. G., Desai, V. P., Reddy, M., & Manokaran, S. (2025) · Proceedings of the National Academy of Sciences India Section B Biological Sciences · doi:10.1007/s40011-025-01710-y · Cited by 2
“This includes studying genetic variations in both the patient’s normal tissues and their cancerous tumors [4].”
Why Clinical Oncologists Should Talk about the Price of Cancer Drugs
Berlinger, N. (2013) · The AMA Journal of Ethic · doi:10.1001/virtualmentor.2013.15.8.jdsc1-1308 · Cited by 2
Fragoulakis, V., Pallis, A. G., Kateilidou, Maniadakis, N. M., & Georgoulias, V. (2012) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s33608 · Cited by 2
“This is due to multiple factors, such as disease prevalence, the considerable share of patients undergoing chemotherapy, treatment length, high health technologies prices, and therapy-induced toxicities.(20,22) Since there are no clinical trials directly comparing the efficacy of a cytotoxic agent (pemetrexed) with sm…”
Die moderne Krebsmedizin: Weniger wäre manchmal mehr
Fey, M. F. (2014) · Therapeutische Umschau · doi:10.1024/0040-5930/a000623 · Cited by 2
…And the only side-effects are good ones
Ornish, D. M. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70227-3 · Cited by 2
Importance of accessible cancer care
Skrabek, P. (2013) · Transfusion and Apheresis Science · doi:10.1016/j.transci.2013.07.015 · Cited by 2
“Despite variations in overall expenditures and funding structure there is considerable consistency in Europe, Canada, Australia and the United States with between 4–7% of health expenditures on cancer care [12].”
BackgroundInfluentialCancer 2015: a longitudinal whole-of-system study of genomic cancer medicine
Thomas, D. M., Fox, S. B., Lorgelly, P. K., Ashley, D. M., Richardson, G. E., Lipton, L. R., Parisot, J. P., Lucas, M., & McNeil, J. J. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.10.009 · Cited by 2
Meyer, N. M., Hao, Y., Landsman-Blumberg, P. B., Johnson, W., Juneau, P. L., & Rogerio, J. W. (2015) · Comparative Effectiveness Research · doi:10.2147/cer.s62090 · Cited by 2
“5 billion was spent on breast cancer treatment in the USA in 2010.(7) In a study of managed care enrollees in 2003–2009, Montero et al estimated the direct health care costs of patients with metastatic breast cancer to be approximately $10,000 per patient per month (PPPM), with some variation based on type of treatmen…”
A ‘year in the life’ of health services research in oncology
Brundage, M., Snyder, C. F., & Bass, B. (2012) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1586/erp.12.50 · Cited by 2
Beyond “Second-Line” in Non–Small Cell Lung Cancer: Therapy and Supportive Care
Martins, R. G., Reynolds, C. H., & Riely, G. J. (2015) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2015.35.e414 · Cited by 2
Möglichkeiten und Grenzen der stratifizierenden Medizin am Beispiel der Onkologie
Ludwig, W.-D. (2012) · Forum · doi:10.1007/s12312-012-0783-y · Cited by 2
The Role of Big Data in Radiation Oncology
Naqa, I. E. (2015) · Advances in bioinformatics and biomedical engineering book series · doi:10.4018/978-1-4666-6611-5.ch008 · Cited by 2
1202 Discussing and prescribing expensive unfunded anticancer drugs in Australia
Karikios, D. J., Mileshkin, L., Martin, A. M., Ferraro, D. A., & Stockler, M. R. (2015) · European Journal of Cancer · doi:10.1016/s0959-8049(16)30506-8 · Cited by 2
Copeland, T. P., Creasman, J. M., Seidenwurm, D. J., & Franc, B. L. (2017) · Current Oncology · doi:10.3747/co.24.3216 · Cited by 2
Gasto en el último año de vida para pacientes que mueren con cáncer
Prada, S. I., & Contreras, J. F. (2018) · Revista Colombiana de Cancerología · doi:10.1016/j.rccan.2018.01.002 · Cited by 2
Therapy of Cancer and Retroviral Diseases
Williams, C. K. O. (2018) · Springer eBooks · doi:10.1007/978-3-319-99362-1_2 · Cited by 2
Gomes, A., & Nunes, A. A. (2019) · Cadernos Saúde Coletiva · doi:10.1590/1414-462x201900040219 · Cited by 2
Hoch, J. S. (2013) · International series in management science/operations research/International series in operations research & management science · doi:10.1007/978-1-4614-6507-2_18 · Cited by 2
Caring for patients with haematological malignancies
Foà, R., & Jaeger, U. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70217-0 · Cited by 2
Quality-adjusted survival as an end point in breast cancer trials
Aj, M., & Simes, R. J. (2013) · Clinical Investigation · doi:10.4155/cli.13.37 · Cited by 2
Fradgley, E. A., Bryant, J., Paul, C. L., Hall, A. E., Sanson‐Fisher, R., & Oldmeadow, C. J. (2016) · Journal of Oncology Practice · doi:10.1200/jop.2016.011023 · Cited by 2
Carrieri, D., & Peccatori, F. A. (2020) · History & Philosophy of the Life Sciences · doi:10.1007/s40656-020-00351-w · Cited by 2
ESMO Open—Cancer Horizons and the future of oncology
Zielinski, C. C. (2016) · ESMO Open · doi:10.1136/esmoopen-2015-000008 · Cited by 2
Fundytus, A. M., Sullivan, R. J., & Booth, C. M. (2020) · Seminars in Oncology · doi:10.1053/j.seminoncol.2020.10.001 · Cited by 2
Self-citationDaveson, B. A., Smith, M., Yi, D., McCrone, P., Grande, G., Todd, C. J., Gysels, M., Costantini, M., Murtagh, F. E., Higginson, I. J., et al. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011619 · Cited by 2
RetractedDixon, P., Martin, R. M., & Harrison, S. (2023) · medRxiv · doi:10.1101/2023.02.06.23285521 · Cited by 2
“Cancer, a major global cause of morbidity and death (1-4), is associated with important economic impacts on patients, carers and health systems (5-8).”
BackgroundKriellaars, Y., Vermaire, J. A., Beugeling, M., Poorter, R. L., Drijvers, J., & Speksnijder, C. M. (2024) · BMC Cancer · doi:10.1186/s12885-024-12172-2 · Cited by 1
“To our knowledge, there is no cost-effectiveness analysis of a PEI for patients with HNC receiving (C/B)RT, while hospitals and insurances need this information due to the increasing financial burden of cancer care [21].”
BackgroundPatient-level simulation models in cancer care: a systematic review
Busschaert, S.-L., Deynse, H. V., Ridder, M. D., & Putman, K. D. (2025) · Frontiers in Public Health · doi:10.3389/fpubh.2025.1335300 · Cited by 1
“The cancer care landscape is rapidly evolving and new additions to the expanding therapeutic armamentarium arrive continuously, often accompanied with stratospheric costs and unclear benefits (154).”
Sex-disaggregated analysis of breast cancer prevalence in Sierra Leone
Osborne, A. (2025) · BMC Cancer · doi:10.1186/s12885-025-14403-6 · Cited by 1
Çağlayan, Ç., Ayer, T., & Ekwueme, D. U. (2025) · INFORMS journal on computing · doi:10.1287/ijoc.2022.0373 · Cited by 1
Li, W., Cong, Y., Liu, X., Lyu, Z., & Chen, K. (2026) · Frontiers in Public Health · doi:10.3389/fpubh.2025.1745506 · Cited by 1
Lievens, Y. N., Weber, D. C., Andratschke, N. H., Azizaj, E., Clementel, E., Fiorino, C., Guckenberger, M., Nuyens, S., Oppong, F. B., Ost, P., et al. (2026) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2026.111615 · Cited by 1
18F-Fluorodeoxyglucose PET Procedures: Health Economic Aspects in Neurology
Guignard, R., Ouvrier, M. J., Krug, B., Otte, A., Darcourt, J., & Dierckx, R. A. J. O. (2014) · Springer eBooks · doi:10.1007/978-3-642-54307-4_2 · Cited by 1
Manufacturer sponsorship bias in economic analyses matters
Kerr, D. J., & Elzawawy, A. M. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.75 · Cited by 1
Self-citationPalliativmedizin: Ein Modell für Comparative Effectiveness Research?
Schmacke, N. (2012) · Zeitschrift für Evidenz Fortbildung und Qualität im Gesundheitswesen · doi:10.1016/j.zefq.2012.06.025 · Cited by 1
Cardiac Troponin T and Advanced Glycation End-Products in Hemodialysis Patients
Taki, K., Tsuruta, Y., & Niwa, T. (2008) · American Journal of Nephrology · doi:10.1159/000127431 · Cited by 1
Hoch, J. S. (2014) · BMC Health Services Research · doi:10.1186/1472-6963-14-s2-o39 · Cited by 1
The impact of new cancer drugs in real practice oncology: a monoinstitutional experience
Jirillo, A., Imbevaro, S., & Mazurek, M. (2012) · Immunopharmacology and Immunotoxicology · doi:10.3109/08923973.2011.648268 · Cited by 1
Challenges of Radiation Oncology in Spain Today
Guedea, F., Ramos, A., & Lara, P. C. (2013) · Reports of Practical Oncology & Radiotherapy · doi:10.1016/j.rpor.2013.10.002 · Cited by 1
John Bradshaw (1918–1989): putting doctors on trial
O’Mahony, S. (2014) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-014-1206-0 · Cited by 1
Funding UK cancer care: time for a level playing field?
Kunkler, I. H. (2013) · International Journal of Clinical Practice · doi:10.1111/ijcp.12092 · Cited by 1
Kelly, C. M., & Kelly, C. M. (2012) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2013.751020 · Cited by 1
What is the Future for Cancer Clinical Trials?
Perrone, F. (2015) · Future Oncology · doi:10.2217/fon.14.183 · Cited by 1
Patient reported outcomes are important in oncology
Koh, C., Young, J. M., & Solomon, M. J. (2013) · Cancer Forum · Cited by 1
Expósito, J., Linares, I., Castillo, I., Martínez, M., Vargas, P., Herruzo, I., Medina, J. A., Palacios, A., Bayo, E., Espino, F. J. P., et al. (2015) · Radiation Oncology · doi:10.1186/s13014-015-0572-8 · Cited by 1
“Given the impediments to conducting clinical trials on RT, further research is warranted to compare its utilization and outcomes in different cancer types among centers with varied technological resources [29, 30].”
BackgroundIntroduction to the Technical Issues of Economic Evaluation
Fragoulakis, V., Mitropoulou, C., Williams, M. S., & Patrinos, G. P. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-801497-4.00004-7 · Cited by 1
Reorganisation of Oncologic Care in Greece: A Proposal
Emmanouilides, C. E. (2015) · Forum of Clinical Oncology · doi:10.1515/fco-2015-0018 · Cited by 1
“(8) The introduction of new expensive drugs has created rigorous control systems with restrictions that vary by country.”
BackgroundEthical challenges in oncology, explored through a series of vignettes.
Tenner, L. L., & Helft, P. R. (2013) · PubMed · Cited by 1
Immunothérapie : une innovation de rupture non soutenable économiquement ?
Thierry, J.-P. (2016) · Bulletin du Cancer · doi:10.1016/s0007-4551(16)30377-0 · Cited by 2
This is a call to oncologists for action
Micó, C., Berrocal, A., Blasco, A., Caballero, C., Iranzo, V., Lobo, M., & Camps, C. (2018) · Clinical & Translational Oncology · doi:10.1007/s12094-018-1887-3 · Cited by 1
Tranvåg, E. J., & Strand, R. (2022) · Human perspectives in health sciences and technology · doi:10.1007/978-3-030-92612-0_14 · Cited by 1
da Silva, M. J. S., & Costa, L. A. (2022) · Jornal de Assistência Farmacêutica e Farmacoeconomia · doi:10.22563/2525-7323.2020.v6.n.1.p.16-25 · Cited by 1
Jiang, K., Zhou, D., Hong, R., Lu, Q., Xu, F., Xia, W., Zheng, Q., & Wang, S. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13020365 · Cited by 1
How to create value with constrained budgets in oncological care? A narrative review
Vrinzen, C. E. J., Bloemendal, H. J., & Jeurissen, P. (2023) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1080/14737167.2023.2253375 · Cited by 2
“In addition, attention should be paid to reducing ‘inappropriate’ care [40].”
BackgroundTuzcu, Ş. A., Kaplan, İ., İbiloğlu, İ., Uyar, A., Güzel, F., Güzel, Y., & Taşdemir, B. (2024) · Revista da Associação Médica Brasileira · doi:10.1590/1806-9282.20230762 · Cited by 1
Provider perceptions of barriers to biosimilar utilization in community oncology practices
Briggs, O., Brown, C. M., Indurlal, P., Garey, J. S., & Johnsrud, M. T. (2024) · Journal of the American Pharmacists Association · doi:10.1016/j.japh.2024.102082 · Cited by 1
The Future of Oncology Palliative Care
Kaasa, S., & Loge, J. H. (2015) · Springer eBooks · doi:10.1007/978-3-662-46202-7_18 · Cited by 1
Palliative Care in General Practice
Cacciapuoti, I., Signorotti, L., Isabella, M., Capelli, O., Rolfini, M., & Brambill, A. (2012) · InTech eBooks · doi:10.5772/36848 · Cited by 1
Wäscher, S., Schildmann, J., & Vollmann, J. (2016) · Der Onkologe · doi:10.1007/s00761-016-0119-0 · Cited by 1
“Dem von einigen Interessenvertretern angeführte Einsparpotenzial durch PM, z. B. durch modifizierte Studiendesigns in der onkologischen Forschung oder eine Verminderung der Anwendung von nicht wirksamen Arzneimitteln in der klinischen Versorgung, stehen weiterhin erhebliche Kosten für neueArzneimittel entgegen,die abs…”
BackgroundChisaki, Y., Nakamura, N., & Yano, Y. (2016) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b16-00623 · Cited by 1
Delivering Safe and Affordable Cancer Surgical Care
Jaiyesimi, R. A. K., & Oshowo, A. (2017) · Springer eBooks · doi:10.1007/978-3-319-52554-9_11 · Cited by 1
Didier Jacqmin, D., Jichlinski, P., Molinier, L., TAILLE, A. D. L., Irani, J., & Malavaud, B. A. (2017) · Urologia Internationalis · doi:10.1159/000477973 · Cited by 1
Die Preisgestaltung von Arzneimittel aus internationaler Perspektive
Hessel, F. P. (2018) · Springer eBooks · doi:10.1007/978-3-658-23016-6_17 · Cited by 1
Authorization Framework for Medical Data
Madadevaiah, G., Prasad, R., Hiremath, A., Dumontier, M., & Dekker, A. L. A. J. (2019) · International Journal of Database Management Systems · doi:10.5121/ijdms.2019.11302 · Cited by 1
“8 However, access to clinical data is longstanding challenge, particularly given the administrative, political and ethical barriers [4].”
BackgroundUse of Micronucleus Assays to Measure DNA Damage Caused by Cytostatic/Antineoplastic Drugs
Gianfredi, V., Acito, M., Salvatori, T., Villarini, M., & Moretti, M. (2019) · Royal Society of Chemistry eBooks · doi:10.1039/9781788013604-00601 · Cited by 1
Moghimi, H., Wickramasinghe, N. S., & Adya, M. P. (2019) · Healthcare delivery in the information age · doi:10.1007/978-3-030-17347-0_11 · Cited by 1
Access to pain management for cancer patients treated under the Brazilian private healthcare system
Santos, M. A., Stefani, L. P. C., Neto, J. P. R., & Stefani, S. D. (2019) · Jornal Brasileiro de Economia da Saúde · doi:10.21115/jbes.v11.n3.p255-62 · Cited by 1
Understanding Molecular Process and Chemotherapeutics for the Management of Breast Cancer
Kumar, A., Masand, N., & Patil, V. M. (2020) · Current Chemical Biology · doi:10.2174/2212796814999200728185759 · Cited by 1
Pirtoli, L., Alia, L., & Zacchini, S. (2021) · Medicus · doi:10.58944/yecp1983 · Cited by 1
Cancer patient survival in Sweden – theory and application
Talbäck, M. (2011) · Figshare · Cited by 1
Kunkler, I. H. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70418-1 · Cited by 1
Metadata
- Authors
- Sullivan, R., Peppercorn, J., Sikora, K., Zalcberg, J., Meropol, N. J., Amir, E., Khayat, D., Boyle, P., Autier, P., Tannock, I. F., Fojo, T., Siderov, J., Williamson, S., Camporesi, S., McVie, J. G., Purushotham, A. D., Naredi, P., Eggermont, A., Brennan, M. F., Steinberg, M. L., De Ridder, M., McCloskey, S. A., Verellen, D., Roberts, T., Storme, G., Hicks, R. J., Ell, P. J., Hirsch, B. R., Carbone, D. P., Schulman, K. A., Catchpole, P., Taylor, D., Geissler, J., Brinker, N. G., Meltzer, D., Kerr, D., & Aapro, M.
- Affiliations
- Guy's Hospital (GB)
- Duke Medical Center (US)
- The University of Melbourne (AU)
- University Hospitals Seidman Cancer Center (US)
- University of Toronto (CA)
- Pitié-Salpêtrière Hospital (FR)
- International Prevention Research Institute (FR)
- National Cancer Institute (US)
- Austin Hospital (AU)
- Northumbria Healthcare NHS Foundation Trust (GB)
- King's College London (GB)
- European Institute of Oncology (IT)
- Umeå University (SE)
- Institut Gustave Roussy (FR)
- Memorial Sloan Kettering Cancer Center (US)
- University of California, Los Angeles (US)
- Vrije Universiteit Brussel (BE)
- Peter MacCallum Cancer Centre (AU)
- University College London (GB)
- Duke University (US)
- Vanderbilt University Medical Center (US)
- Association of the British Pharmaceutical Industry (GB)
- University of London (GB)
- Susan G. Komen Breast Cancer Foundation (US)
- University of Chicago (US)
- University of Oxford (GB)
- Clinique de Genolier (CH)
- Corresponding author
- Sullivan, Richard
- ORCID
- Sullivan, Richard
- Peppercorn, Jeffrey
- Sikora, Karol
- Zalcberg, John
- Meropol, Neal J
- Amir, Eitan
- Boyle, Peter
- Autier, Philippe
- Tannock, Ian F
- Fojo, Tito
- Siderov, Jim
- Williamson, Steve
- Camporesi, Silvia
- Purushotham, Arnie D
- Naredi, Peter
- Eggermont, Alexander
- Brennan, Murray F
- Steinberg, Michael L
- McCloskey, Susan A
- Verellen, Dirk
- Storme, Guy
- Hicks, Rodney J
- Schulman, Kevin A
- Taylor, David
- Geissler, Jan
- Meltzer, David
- Kerr, David
- Aapro, Matti
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2011-09
- Volume
- 12
- Issue
- 10
- Pages
- 933-980
- ISSN
- 1470-2045 (ISSN-L)
- OpenAlex
- W2111285159
- Cited by
- 718
- References
- 279
- Citations by year
- 2026: 21 · 2025: 24 · 2024: 34 · 2023: 16 · 2022: 33 · 2021: 43 · 2020: 40 · 2019: 32 · 2018: 60 · 2017: 45 · 2016: 56 · 2015: 67 · 2014: 75 · 2013: 81 · 2012: 76
- FWCI
- 199.54
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Lancet Oncology (publishedVersion)
- PubMed (publishedVersion)
- Strathprints: The University of Strathclyde institutional repository (University of Strathclyde) (acceptedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Research Portal (King's College London) (submittedVersion)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Funders
- Conquer Cancer Foundation
- King's College Hospital NHS Foundation Trust
- National Institute for Health and Care Research
- Department of Health and Social Care
- King's College London
- Topics
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Economic and Financial Impacts of Cancer
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Advances in Oncology and Radiotherapy
- Keywords
- cancer costs, high-income countries, value-based pricing, access to cancer treatment, health equity, regulatory regimes, health policy, overuse of health care
- MeSH terms
- Australia, Cost-Benefit Analysis, Europe, Health Expenditures, Health Policy, Health Services Accessibility, Health Services Misuse, Health Services Research, Humans, Insurance, Health, Neoplasms, Socioeconomic Factors, United States, Cost Savings, Health Care Costs, Health Care Reform, Models, Economic, Delivery of Health Care, Integrated, Healthcare Disparities
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
